LAVAL, May 8 /PRNewswire-FirstCall/ - LAB International Inc. (“LAB”), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that it will report financial results for the first quarter of fiscal 2006 ended March 31, 2006 on Friday May 12, 2006.
LAB will host a conference call at 10:00 a.m., on Friday May 12, 2006. Interested parties may also access the conference call by webcast at www.labinc.ca.
The telephone number to access the conference call is 1-866-249-2165. A replay of the call will be available until May 19, 2006. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21188184 (pound key).
About LAB International
LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company’s TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies. LAB Research is a profitable and growing contract research services division supporting its clients base from state-of-the-art facilities in Canada, the US, Denmark and Hungary.
LAB’s common shares trade on The Toronto Stock Exchange (“TSX”) under the symbol “LAB”, on the Frankfurt Regulated Unofficial Market under the symbol “LD9.F” and on XETRA under the symbol “LD9.DE” with 71.5 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
LAB INTERNATIONAL INC.
CONTACT: visit LAB’s website at www.labinc.ca, or contact: Luc Mainville,Chief Operating Officer, (450) 973-2240 ext. 1206, Fax: (450) 973-2259,mainvillel@labinc.ca; Frederic Dumais, Vice-President, Investor Relations,(450) 973-2240 ext. 1207Fax: (450) 973-2259, dumaisf@labinc.ca
